16,258 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,258 shares of the biopharmaceutical company’s stock, valued at approximately $339,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. abrdn plc purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth $10,115,000. Jane Street Group LLC increased its position in Catalyst Pharmaceuticals by 245.4% in the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after buying an additional 285,564 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $4,936,000. Pacer Advisors Inc. raised its stake in shares of Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after buying an additional 151,495 shares during the period. Finally, Barclays PLC lifted its position in shares of Catalyst Pharmaceuticals by 129.4% during the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after buying an additional 140,129 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Down 0.1 %

Catalyst Pharmaceuticals stock opened at $25.72 on Wednesday. The firm’s fifty day moving average is $22.53 and its 200 day moving average is $21.72. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16. The company has a market cap of $3.12 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 3.31 and a beta of 0.84.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CPRX has been the subject of a number of analyst reports. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.